U.S. Markets close in 1 hr 59 mins

Amneal Pharmaceuticals, Inc. (AMRX)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
4.0000+0.0200 (+0.50%)
As of 11:00AM EST. Market open.

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
http://www.amneal.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees5,500

Key Executives

NameTitlePayExercisedYear Born
Mr. Chirag K. PatelCo-Founder, Co-CEO, Pres & Director62.97kN/A1967
Mr. Chintu Patel R.Ph., R.PhCo-Founder, Co-CEO & Director64.6kN/A1972
Mr. Andrew S. BoyerExec. VP & Chief Commercial Officer of Generics675.09kN/A1966
Mr. Anastasios G. KonidarisExec. VP & CFON/AN/A1967
Mr. Stephen J. ManzanoSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1965
Mr. James LuceExec. VP of Sales & MarketingN/AN/AN/A
Ms. Nikita ShahExec. VP and Chief HR Officer & Strategic Planning OfficerN/AN/A1978
Mr. Sanjiv PatelSr. VP of OperationsN/AN/AN/A
Ms. Candis EdwardsSr. VP of Regulatory AffairsN/AN/AN/A
Mr. Joseph Todisco MBAExec. VP & Chief Commercial Officer of SpecialtyN/AN/A1976
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

Corporate Governance

Amneal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 6. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 4; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.